A Phase 2 interventional study of capecitabine and Oxaliplatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-03.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.
Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 17th largest by enrollment of the 173 interventional ones that give a count, is one of 11 that started in 2005, is one of 100 in phase 2, and was the 22nd registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in France, Germany, Italy and 1 more country
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Nizhny Novgorod Regional Clinical Oncology Center · Sites in Russian Federation
Ages 70–90
Henry Ford Health System · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 124 · Phase 3 37 · Phase 4 8
First in 1998; this study’s year is marked. 11 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 435 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 55 across the 173 interventional studies. Of the 111 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 179 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 13th largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2005, is one of 32 in phase 2, and was the 15th registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
9 of the studies testing capecitabine in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05700656The Netherlands Cancer InstituteGalunisertib Combined With Capecitabine in Advanced CRC With PM | 2026-12 |
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT07051785Liu HuangFruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | 2027-07-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 179 studies testing capecitabine in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 2-arm study evaluated the efficacy and safety of 2 different treatment schedules of oral Xeloda with intravenous (IV) Eloxatin (oxaliplatin) and IV bevacizumab (Avastin) as a first-line treatment in patients with locally advanced or metastatic colorectal cancer. Patients were randomized to receive either: 1) Xeloda 850 mg/m\^2 orally twice a day (po bid) on Days 1-14, oxaliplatin 130 mg/m\^2 IV on Day 1, and Avastin 7.5 mg/kg IV on Day 1 of each 3-week cycle; or 2) Xeloda 1500 mg/m\^2 po bid on Days 1-7, oxaliplatin 85 mg/m\^2 IV on Day 1 and Avastin 5 mg/kg IV on Day 1 of each 2-week cycle. The anticipated time on study treatment was 1-2 years, and the target sample size was 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: capecitabine · Drug: Oxaliplatin · Drug: bevacizumab
Drug: capecitabine · Drug: Oxaliplatin · Drug: bevacizumab
850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
130 mg/m\^2 IV on Day 1 of each 3-week cycle
7.5 mg/kg IV on Day 1 of each 3-week cycle
1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
85 mg/m\^2 IV on Day 1 of each 2-week cycle
5 mg/kg IV on Day 1 of each 2-week cycle
Progression-free Survival (PFS)
Progression-free survival was defined as the time from the date of randomization to the first occurrence of having documented disease progression or death due to any cause, whichever comes first. Progression was based on tumor assessments made by the investigators according to Response Evaluation Criteria in Solid Tumors (RECIST).
Time frame: Time to disease progression or death (through follow-up phase)
Overall Survival
Overall survival was defined as the time from the date of randomization to the date of death, for any cause.
Time frame: Time to death (through follow-up phase): Approximate Median of 718 days
Best Overall Clinical Response
Overall response rate was assessed according to RECIST (the best response recorded from the time of randomization to the first CR or PR. The patient's overall best response was complete response (CR), partial response (PR) (CR and PR considered "responders"), stable disease (SD), or progressive disease (PD). To be assigned a status of complete response (CR) or partial response (PR), changes in tumor measurements were confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met.
Time frame: Through follow-up phase: Approximate Median of 318 days
Duration of Overall Clinical Response (CR or PR)
Among tumor responders (i.e., patients with overall best response of CR or PR), duration of overall response was measured from the time criteria were first met for CR or PR (whichever status was recorded first) to the date of either recurrent/progressive disease was objectively documented or death from any cause.
Time frame: Time to Disease Progression or Death (through follow-up phase): Approximate Median of 302 days
| Milestone | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab |
|---|---|---|
| Started | 217 | 218 |
| Safety population | 208 | 211 |
| Completed | 7 | 3 |
| Not completed | 210 | 215 |
Progression-free survival was defined as the time from the date of randomization to the first occurrence of having documented disease progression or death due to any cause, whichever comes first. Progression was based on tumor assessments made by the investigators according to Response Evaluation Criteria in Solid Tumors (RECIST).
| Days | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab |
|---|---|---|
| Progression-free Survival (PFS) | 287 (234 to 329) | 273 (231 to 313) |
Overall survival was defined as the time from the date of randomization to the date of death, for any cause.
| Days | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab |
|---|---|---|
| Overall Survival | 852 (605 to 1052) | 662 (595 to 762) |
Overall response rate was assessed according to RECIST (the best response recorded from the time of randomization to the first CR or PR. The patient's overall best response was complete response (CR), partial response (PR) (CR and PR considered "responders"), stable disease (SD), or progressive disease (PD). To be assigned a status of complete response (CR) or partial response (PR), changes in tumor measurements were confirmed by repeat assessments performed no less than 4 weeks after the criteria for response were first met.
| Patients | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab |
|---|---|---|
| Nonresponders (without CR or PR) | 145 | 167 |
| Responders (with CR or PR) | 72 | 51 |
| Complete Response (CR) | 2 | 3 |
| Partial Response (PR) | 70 | 48 |
Among tumor responders (i.e., patients with overall best response of CR or PR), duration of overall response was measured from the time criteria were first met for CR or PR (whichever status was recorded first) to the date of either recurrent/progressive disease was objectively documented or death from any cause.
| Days to event | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab |
|---|---|---|
| Duration of Overall Clinical Response (CR or PR) | 281 (225 to 397) | 316 (244 to 522) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| XELOX Q3W + Bevacizumab | — | 84/208 (40.4%) | 202/208 (97.1%) |
| XELOX Q2W + Bevacizumab | — | 94/211 (44.5%) | 206/211 (97.6%) |
| Event | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 20/208 | 22/211 |
| DehydrationMetabolism and nutrition disorders | 21/208 | 18/211 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 8/208 | 3/211 |
| Abdominal PainGastrointestinal disorders | 3/208 | 6/211 |
| Mucosal InflammationGeneral disorders | 0/208 | 6/211 |
| Deep Vein ThrombosisVascular disorders | 5/208 | 2/211 |
| Small Intestinal ObstructionGastrointestinal disorders | 4/208 | 4/211 |
| VomitingGastrointestinal disorders | 4/208 | 4/211 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 4/208 | 3/211 |
| GastroenteritisInfections and infestations | 4/208 | 3/211 |
| Event | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 131/208 | 152/211 |
| NauseaGastrointestinal disorders | 117/208 | 139/211 |
| FatigueGeneral disorders | 123/208 | 105/211 |
| Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders | 50/208 | 86/211 |
| VomitingGastrointestinal disorders | 74/208 | 81/211 |
| Neuropathy PeripheralNervous system disorders | 67/208 | 57/211 |
| AnorexiaMetabolism and nutrition disorders | 51/208 | 58/211 |
| Abdominal PainGastrointestinal disorders | 55/208 | 49/211 |
| Peripheral Sensory NeuropathyNervous system disorders | 51/208 | 40/211 |
| Weight DecreasedInvestigations | 31/208 | 45/211 |
| Age Continuous(years) | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab | Total |
|---|---|---|---|
| Mean | 60.6 ± 11.45 | 60.8 ± 12.17 | 60.7 ± 11.81 |
| Sex: Female, Male(Participants) | XELOX Q3W + Bevacizumab | XELOX Q2W + Bevacizumab | Total |
|---|---|---|---|
| Female | 89 | 96 | 185 |
| Male | 128 | 122 | 250 |
No study locations are listed for this record.
The record gives a start of Jul 2005 and a primary completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capecitabine